June 04, 2021
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
June 03, 2021
Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference
June 01, 2021
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
We hosted a virtual Investor Day in March 2021 to discuss our research and development strategy and portfolio, including updates from our nemvaleukin alfa development program in immuno-oncology and new preclinical neuroscience and immuno-oncology programs.
We’re proud to recognize Joyanna Wesche-Blake, Senior Director of IT, as our 2021 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.
In this “The Medicine Maker” article, our Chief Operating Officer, Blair Jackson, discusses how to determine corporate readiness when exploring a new therapeutic area and reflects on Alkermes' entry into oncology.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.